Skip to content
10-Q

Quarterly Report

Amneal Pharmaceuticals, Inc. AMRX

0001723128-25-000022

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 313.42M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $2.15B
Long Term Debt Q1 2025 · Dec 31, 2024 $2.16B
Short Term Debt Q1 2025 · Mar 31, 2025 $31.79M
Short Term Debt Q1 2025 · Dec 31, 2024 $224.21M
Stockholders Equity Q1 2025 · Mar 31, 2025 −$131.67M
Stockholders Equity Q1 2025 · Dec 31, 2024 −$109.27M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.08B
Current Liabilities Q1 2025 · Dec 31, 2024 $1.13B
Current Assets Q1 2025 · Mar 31, 2025 $1.51B
Current Assets Q1 2025 · Dec 31, 2024 $1.59B
Total Assets Q1 2025 · Mar 31, 2025 $3.37B
Total Assets Q1 2025 · Dec 31, 2024 $3.5B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $110.55M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $46.52M
Shares Diluted Q1 2025 · Mar 31, 2024 307.28M sh
Capex Q1 2025 · Mar 31, 2024 $9.2M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$4.41M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.30
Eps Basic Q1 2025 · Mar 31, 2024 −$0.30
Sga Expense Q1 2025 · Mar 31, 2024 $112.6M
Rd Expense Q1 2025 · Mar 31, 2024 $39.3M
Net Income Q1 2025 · Mar 31, 2024 −$91.64M
Operating Income Q1 2025 · Mar 31, 2024 −$10.75M
Gross Profit Q1 2025 · Mar 31, 2024 $238.06M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $421.13M
Revenue Q1 2025 · Mar 31, 2024 $659.19M